Home

asdasd22d
Title: Slide 2
Title Credit Type Therapeutic Area Format
Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies CME, CNE, CPE Oncology On-Demand Webcast
New and Emerging Agents in HCL CME, CNE, CPE Oncology On-Demand Webcast
Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors CME, CNE, CPE Oncology On-Demand Webcast
Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma CME, CNE, CPE Oncology On-Demand Webcast
Treatment for Marginal Zone Lymphoma: Should it be Different from FL? CME, CNE, CPE Oncology On-Demand Webcast
Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches CME, CNE, CPE Oncology On-Demand Webcast
New and Emerging Agents in MCL CME, CNE, CPE Oncology On-Demand Webcast
New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies CME, CNE, CPE Oncology On-Demand Webcast
First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy CME, CNE, CPE Oncology On-Demand Webcast
Positioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease CME, CNE, CPE Oncology On-Demand Webcast
Looking to the Future With Hope: Advances in the Treatment of AML CME, CNE, CPE Oncology On-Demand Webcast
Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape CME, CNE, CPE Oncology On-Demand Webcast

Pages